The prevalence of any substance use disorder (SUD) and schizophrenia comorbidity is around 42%. This dual diagnosis is associated with a higher severity of symptoms, more relapses and hospitalizations, an increased risk of nonadherence, and worse prognosis. The treatment of this dual diagnosis is markedly challenging. To date, pharmacotherapy studies in this dual diagnosis have been limited. Antipsychotics continue to be the treatment of choice, and the use of second-generation instead of first-generation antipsychotic medications may be preferred due to greater tolerability and decreased likelihood for developing extrapyramidal side effects in people with SUD. However, there is no evidence for any differential benefit for one antipsychotic over another for patients with psychosis and coexisting SUD. Similarly, the evidence of superiority between long-acting injectable antipsychotics and oral antipsychotics is very scarce.Reference Crockford and Addington ¹

Drugs with a dopamine D₂ receptor partial agonism have been investigated as a possible target of treatment for patients with psychosis and SUD comorbidity during the last decade. This pharmacological mechanism of action provides a better tolerability over dopaminergic antagonists as a main advantage. Moreover, partial agonists are less disruptive on the functionality of neurons because they tend to normalize and stabilize the tone of dopaminergic neurotransmission. All of this has promoted that psychiatrists on current routine practice consider the use of partial agonists, like aripiprazole, as the second option in the acute setting as well as the treatment of choice in the maintenance setting for patients with psychosis and SUD.Reference Clerici, de Bartolomeis and De Filippis ²

In recent years, preclinical and clinical research have shown dopamine D₃ receptors as a promising therapeutic target for many neuropsychiatric disorders, such as psychotic disorders or SUD, among others. Anatomically, D₃ receptors show a high distribution in the mesolimbic system, brain area where are structures as nucleus accumbens and which is critically involved in the regulation of motivation and reward. Functionally, evidence suggests that D₃ receptor is an autoreceptor with inhibitory effects on dopamine impulse flow and dopamine release. Experimental drugs targeting specifically D₃ receptors, both antagonists and partial agonists, have constantly been investigated for treating schizophrenia. It has suggested that blockade of D₃ receptors could improve cognitive and negative domains of schizophrenia. Moreover, these receptors haven been related to SUD suggesting that they are involved in drug-related reward and drug-intake, as well as in behavioral sensitization, including reinstatement and drug-seeking behavior. In fact, increases in D₃ receptors expression have been found in animals chronically exposed to psychostimulant drugs.Reference Leggio, Bucolo and Platania ³

Recently, US Food and Drug Administration and European Medicines Agency have approved the newer antipsychotic cariprazine for acute and maintenance treatment of adults with schizophrenia. Cariprazine differs from other antipsychotics in its mechanism of action. It is a dopamine D₃ and D₂ receptor partial agonist, with 10-fold higher affinity for D₃ receptors than for D₂ receptors. In fact, it is the dopamine partial agonist antipsychotic, compared with aripiprazole and brexpiprazole, with the highest affinity for D₃ receptor.Reference Calabrese, Tarazi and Racagni ⁴ This pharmacodynamic profile could be beneficial in patients with psychosis and SUD. Although there is not enough evidence, cariprazine has demonstrated anti-abuse potential in a preclinical study. Specifically, cariprazine, as well as aripiprazole and bifeprunox, was able to reduce the rewarding effect of cocaine and attenuated relapse to cocaine seeking in rats. These results suggest that cariprazine may have relapse-preventing potential in addition to its well-established antipsychotic efficacy.Reference Román, Gyertyán and Sághy ⁵

In conclusion, antipsychotics with a dopamine partial agonism seem to provide potential clinical advantages in the treatment of psychosis and SUD comorbidity. Although there is more evidence with those drugs that has more specificity on dopamine D₂ receptor, recent studies postulate drugs targeting dopamine D₃ receptor as a pharmacological alternative to consider. Further research and empirical evidence from clinical practice routine will clarify its usefulness and efficacy in this dual diagnosis.